{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:26:30Z","timestamp":1789457190999,"version":"build-2803163510"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Cancer of unknown primary (CUP) is evolving from a diagnosis of exclusion treated with empirical chemotherapy to a molecularly defined entity amenable to precision-based interventions. This heterogeneous entity, comprising 2\u20133% of all metastatic malignancies, encompasses diverse cancers with clinically occult primary sites at diagnosis after a thorough workup. Recent landmark trials including CUPISCO and Fudan CUP-001 have demonstrated significant survival improvements with molecularly guided therapies compared to empirical chemotherapy, fundamentally enhancing and complementing traditional organ-centric treatment paradigms. This review synthesizes the current evidence supporting molecular diagnostics, tumor-agnostic therapies, and precision-based approaches in CUP management. We examine the clinical utility of comprehensive genomic profiling, gene expression profiling, and liquid biopsy technologies, while addressing implementation challenges and future directions. The integration of molecular tumor boards and the emergence of tissue\/tissue-of-origin agnostic therapies herald a new era where CUP transitions from therapeutic nihilism to personalized oncology. As molecular technologies advance and targeted therapies proliferate, CUP may no longer represent a diagnosis of exclusion but rather an opportunity for molecularly informed precision care.<\/jats:p>","DOI":"10.3390\/jpm16020080","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:48:01Z","timestamp":1770115681000},"page":"80","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular-Guided Precision Oncology in Cancer of Unknown Primary: A State-of-the-Art Perspective"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Rassy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France"},{"name":"CESP, INSERM U1018, Universit\u00e9 Paris-Saclay, 94807 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-3741","authenticated-orcid":false,"given":"Frank A.","family":"Greco","sequence":"additional","affiliation":[{"name":"Sarah Cannon Cancer Center, Tennessee Oncology, Greco-Hainsworth Centers for Research, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.ejca.2007.06.023","article-title":"Switching benchmarks in cancer of unknown primary: From autopsy to microarray","volume":"43","author":"Pentheroudakis","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_2","unstructured":"Society, A.C. (2026, January 01). Key Statistics for Cancers of Unknown Primary. Available online: https:\/\/www.cancer.org\/cancer\/types\/cancer-unknown-primary\/about\/key-statistics.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2400041","DOI":"10.1200\/OA-24-00041","article-title":"Cancer of Unknown Primary Site: A New Era of Practice-Changing Approaches to Diagnosis, Staging, and Precision Therapy","volume":"1","author":"Greco","year":"2024","journal-title":"JCO Oncol. Adv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","article-title":"Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary","volume":"77","author":"Kato","year":"2017","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606","volume":"34","author":"Bochtler","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): An open-label, randomised, phase 2 study","volume":"404","author":"Bochtler","year":"2024","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","article-title":"Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): A randomised controlled trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41571-025-01060-8","article-title":"Rethinking cancer of unknown primary: From diagnostic challenge to targeted treatment","volume":"22","author":"Pouyiourou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/sj.bjc.6604315","article-title":"Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary","volume":"98","author":"Bridgewater","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling with Carboplatin and Paclitaxel for Patients with Cancer of Unknown Primary Site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115447","DOI":"10.1016\/j.ejca.2025.115447","article-title":"Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis","volume":"222","author":"Labaki","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.annonc.2025.07.007","article-title":"Cancer of unknown primary site and TNM staging: A new paradigm for patient management","volume":"36","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1002\/onco.13744","article-title":"A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience","volume":"26","author":"Pauli","year":"2021","journal-title":"Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-022-03318-6","article-title":"Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: A large-scale multicenter study of 1417 patients","volume":"20","author":"Sun","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1634\/theoncologist.2011-0466","article-title":"A Second-Generation MicroRNA-Based Assay for Diagnosing Tumor Tissue Origin","volume":"17","author":"Meiri","year":"2012","journal-title":"Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1002\/onco.13597","article-title":"Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design","volume":"26","author":"Ross","year":"2020","journal-title":"Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1476-4598-12-57","article-title":"Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary","volume":"12","author":"Pentheroudakis","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: A multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1339","DOI":"10.1016\/j.annonc.2023.10.104","article-title":"LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes","volume":"34","author":"Wasan","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.09.035","article-title":"Liquid biopsy: A new diagnostic, predictive and prognostic window in cancers of unknown primary","volume":"105","author":"Khaled","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_24","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): A tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jmoldx.2011.04.004","article-title":"Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification","volume":"13","author":"Erlander","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2007.14.4378","article-title":"Molecular Profiling of Carcinoma of Unknown Primary and Correlation with Clinical Evaluation","volume":"26","author":"Varadhachary","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"bbae028","DOI":"10.1093\/bib\/bbae028","article-title":"New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: Progress and challenges","volume":"25","author":"Ma","year":"2024","journal-title":"Brief. Bioinform."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.6004\/jnccn.2011.0120","article-title":"Gene Expression Analysis and Immunohistochemistry in Evaluation of Cancer of Unknown Primary: Time for a Patient-Centered Approach","volume":"9","author":"Handorf","year":"2011","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","article-title":"AI-based pathology predicts origins for cancers of unknown primary","volume":"594","author":"Lu","year":"2021","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41416-025-03073-7","article-title":"Cancer of unknown primary: The hunt for its elusive tissue-of-origin\u2014Is it time to call off the search?","volume":"133","author":"Spurgeon","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00428-023-03708-1","article-title":"The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: An updated review","volume":"484","author":"Lorkowski","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.tranon.2021.101016","article-title":"Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type","volume":"14","author":"Abraham","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","article-title":"A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary","volume":"15","author":"Conway","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Dao, J., Conway, P.J., Subramani, B., Meyyappan, D., Russell, S., and Mahadevan, D. (2023). Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713219"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: Promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/s41467-025-57941-0","article-title":"Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals","volume":"16","author":"Sledge","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.soc.2023.12.001","article-title":"Tissue-Agnostic Cancer Therapy Approvals","volume":"33","author":"Gouda","year":"2024","journal-title":"Surg. Oncol. Clin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104086","DOI":"10.1016\/j.critrevonc.2023.104086","article-title":"Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?","volume":"190","author":"Fanale","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"113540","DOI":"10.1016\/j.ejca.2024.113540","article-title":"Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies","volume":"200","author":"Zaun","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial","volume":"6","author":"Hayashi","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1007\/s00432-023-04741-y","article-title":"Cancer of unknown primary (CUP) through the lens of precision oncology: A single institution perspective","volume":"149","author":"Weiss","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e192597","DOI":"10.1001\/jamanetworkopen.2019.2597","article-title":"Application of a Neural Network Whole Transcriptome\u2013Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers","volume":"2","author":"Grewal","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.trecan.2022.11.003","article-title":"Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies","volume":"9","author":"Bhamidipati","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.trecan.2023.07.002","article-title":"Tumor-agnostic drug development in dMMR\/MSI-H solid tumors","volume":"9","author":"Bhamidipati","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-23-0090","article-title":"Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications","volume":"29","author":"Gouda","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cncr.35085","article-title":"Revolutionizing cancer drug development: Harnessing the potential of basket trials","volume":"130","author":"Subbiah","year":"2024","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Wu, S., and Thawani, R. (2025). Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17050801"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/80\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:58:37Z","timestamp":1770116317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jpm16020080"],"URL":"https:\/\/doi.org\/10.3390\/jpm16020080","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}